Search Bar & Filters
Found 72 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effects of L606 in people with pulmonary hypertension caused by interstitial lung disease PH-ILD, WHO Group 3. The study focuses on whether L606 helps participants walk further in six minutes, using the six-minute walk test as a main measure. It also examines how long it takes for PH-ILD to worsen under treatment, alongside close monitoring for any side effects. Participants are randomly assigned to receive either L606, a liposomal form of treprostinil delivered by inhalation with a nebulizer, or a placebo that looks like L606 but contains no active medicine. After the initial blinded phase, participants may join an open-label extension where all receive L606. The study uses a parallel design with quadruple masking to compare outcomes between groups. During the trial, participants will attend visits to assess walking distance at multiple time points, monitor lung health, and watch for side effects. Key measurements include changes in six-minute walk distance at 16 and 24 weeks and the time until worsening events like hospitalization or lung transplant. The study is expected to continue until 2031, with safety and efficacy carefully tracked throughout.
Actively Recruiting
Researchers are evaluating inhaled mosliciguat in adults with pulmonary hypertension associated with interstitial lung disease PH-ILD. This Phase 3, multicenter, randomized, double-blind, placebo-controlled trial aims to study the safety and efficacy of this treatment in improving exercise capacity measured by the 6-minute walk distance. Pulmovant, Inc. is sponsoring this study to better understand treatment options for this condition. Participants will be randomly assigned to receive either inhaled mosliciguat or a matching placebo daily for 24 weeks during the blinded treatment period. Those who complete this phase may continue into an extension period where all receive mosliciguat. The treatment is administered via a dry powder inhaler, with three dose levels of mosliciguat evaluated. Throughout the study, participants will undergo assessments including the 6-minute walk test, right heart catheterization to confirm pulmonary hypertension, and symptom questionnaires. Researchers will monitor changes in pulmonary vascular resistance, biomarker levels such as NT-proBNP, and clinical worsening events. The total study duration extends beyond 24 weeks with continued safety and efficacy monitoring through the extension phase.
Actively Recruiting
This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effects of ROC-101 in adults diagnosed with Pulmonary Arterial Hypertension PAH or Pulmonary Hypertension associated with Interstitial Lung Disease ILD-PH. This Phase 2a, open-label, single-arm exploratory study includes participants classified under World Health Organization WHO Group I PAH or Group III ILD-PH, aiming to assess oral doses of ROC-101 alongside standard care. Participants will receive oral ROC-101 daily, starting at 10 mg and gradually increasing to 40 mg for a 24-week treatment period, combined with standard of care therapy. After this period, participants may continue in a long-term extension phase until the study program concludes or regulatory approval is granted. Evaluations include hemodynamic measurements obtained through right heart catheterization and monitoring of adverse events. Throughout the study, participants will undergo assessments such as pulmonary function tests, exercise capacity tests 6-minute walk distance, and right heart catheterization measurements at baseline and 24 weeks. Researchers will track changes in pulmonary vascular resistance and safety outcomes, along with various cardiac and respiratory function parameters. The total study duration includes the initial 24-week treatment phase followed by an optional long-term extension period for continued monitoring.
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate LTP001 treatment in both healthy adults and participants with pulmonary arterial hypertension PAH. It explores safety, tolerability, and how the body processes LTP001 in healthy volunteers Part A, and assesses safety and efficacy in PAH patients Part B followed by an extended safety period. The study is designed as a randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. Participants in Part A receive single and multiple ascending doses of LTP001 or placebo to understand pharmacokinetics and safety over 35 days. Part B involves treatment with LTP001 or placebo alongside stable standard PAH therapies, with treatment periods up to 106 weeks including a 24-week initial evaluation and a longer safety extension. Both parts include placebo comparison and dose escalation in a parallel study model. Throughout the study, participants undergo monitoring for adverse events, changes in pulmonary vascular resistance, and functional assessments such as the Six-minute Walk Test and WHO functional class. Blood tests measure biomarkers like NT-proBNP. Safety and pharmacokinetic data are collected frequently in Part A, while Part B includes long-term efficacy and safety evaluations up to 106 weeks. Participant involvement includes regular visits for treatment administration, assessments, and follow-up until study completion in late 2028.
Actively Recruiting
Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.
1-10 of 72
1